RxDoctor Payments Data

Christine Valenta

Gerontology · Tucson, AZNPI 1093791055

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 28.9% of the total. That places this record below the midpoint for gerontology clinicians in AZ, where the typical reported total is $478.

$244in general payments, 2019–2025

Across 13 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$70
  • AbbVie$46
  • Otsuka America Pharmaceutical, Inc.$45
  • Bridgebio Pharma, Inc.$21
  • AstraZeneca$19
  • Pfizer$15
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$244 in reported general payments places this provider in the 40th percentile of 99 gerontology providers in Arizona.

See all gerontology providers in Arizona

Medicare billing

Part B allowed, 2024
$40,594
Medicare patients
84
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$84,202
JanuviaSitagliptin Phosphate44$28,727
XareltoRivaroxaban34$18,437
NamzaricMemantine Hcl/Donepezil Hcl13$7,621
Mirtazapine270$6,565
GemtesaVibegron12$6,077
Levothyroxine Sodium339$4,358
Metformin Hcl75$4,323
Duloxetine Hcl101$3,962
Atorvastatin Calcium273$3,920
Gabapentin167$3,910
Buspirone Hcl134$2,921
Trazodone Hcl208$2,878
SymbicortBudesonide/Formoterol Fumarate11$2,687
Oxybutynin Chloride ErOxybutynin Chloride66$2,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$84,202127 claims
AbbVieNamzaric$46$7,62113 claims
AstraZenecaSymbicort$19$2,68711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 99 gerontology providers in Arizona.

Other gerontology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →